- Home
- XAIR vs GTBP Comparison
XAIR vs GTBP Comparison
Compare XAIR & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | GTBP |
|---|---|---|
| Founded | 2011 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 8.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | XAIR | GTBP |
|---|---|---|
| Price | $1.21 | $0.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 22.5M | 1.5M |
| Earning Date | 02-13-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,802,000.00 | N/A |
| Revenue This Year | $127.85 | N/A |
| Revenue Next Year | $179.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $0.67 | $0.54 |
| 52 Week High | $10.40 | $3.85 |
Technical Indicators
Market Signals| Indicator | XAIR | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 42.62 |
| Support Level | $1.43 | $0.69 |
| Resistance Level | $2.26 | $0.74 |
| Average True Range (ATR) | 0.33 | 0.05 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 20.53 | 7.78 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.